
    
      This study began with a 3-arm Lead-in portion to determine the oral (PO) dosing (200 or 250
      milligrams [mg]) of eravacycline to be used with intravenously (IV) administered eravacycline
      for the Pivotal portion (2 arms). A PO dose of 200 mg was selected based on the unblinded
      Lead-in analysis.
    
  